Skip to content

Study · In vitro (cells) · helicobacter pylori · 2009

4 results

Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice.

Leszczyńska K, Namiot A, Fein DE, Wen Q, Namiot Z, Savage PB, Diamond S, Janmey PA, Bucki R

BMC microbiology3 Sept 2009Cited by 40 (Europe PMC)

PMID19728885 (opens in a new tab)PMCIDPMC2748089 (opens in a new tab)DOI10.1186/1471-2180-9-187 (opens in a new tab)PepBankPUB-19728885
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundThe worldwide appearance of drug-resistant strains of H. pylori motivates a search for new agents with therapeutic potential against this family of bacteria that colonizes the stomach, and is associated with adenocarcinoma development. This study was designed to assess in vitro the anti-H. pylori potential of cathelicidin LL-37 peptide, which is naturally present in gastric juice, its optimized synthetic analog WLBU2, and the non-peptide antibacterial agent ceragenin CSA-13.ResultsIn agreement with previous studies, increased expression of hCAP-18/LL-37 was observed in gastric mucosa obtained from H. pylori infected subjects. MBC (minimum bactericidal concentration) values determined in nutrient-containing media range from 100-800 microg/ml for LL-37, 17.8-142 microg/ml for WLBU2 and 0.275-8.9 microg/ml for ceragenin CSA-13. These data indicate substantial, but widely differing antibacterial activities against clinical isolates of H. pylori. After incubation in simulated gastric juice (low pH with presence of pepsin) CSA-13, but not LL-37 or WLBU2, retained antibacterial activity. Compared to LL-37 and WLBU2 peptides, CSA-13 activity was also more resistant to inhibition by isolated host gastric mucins.ConclusionThese data indicate that cholic acid-based antimicrobial agents such as CSA-13 resist proteolytic degradation and inhibition by mucin and have potential for treatment of H. pylori infections, including those caused by the clarithromycin and/or metronidazole-resistant strains.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In vitro, LL‑37 had minimum bactericidal concentrations of 100-800 microg/ml against clinical isolates of H. pylori in nutrient-containing media.

    In plain wordsIn lab tests, LL‑37 killed H. pylori clinical isolates only at high concentrations.

    Peptide
    LL-37
    Outcome
    Not applicableMBC against clinical H. pylori isolates
    Study

    Helicobacter pylorin: not reported in source

    clinical isolates in nutrient-containing media
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    MBC
    100 to 800 microg/ml
    clinical H. pylori isolates

    Source sentences

    Summary
    MBC (minimum bactericidal concentration) values determined in nutrient-containing media range from 100-800 microg/ml for LL-37
    1 context sentence
    Summary · context
    This study was designed to assess in vitro the anti-H. pylori potential of cathelicidin LL-37 peptide, which is naturally present in gastric juice, its optimized synthetic analog WLBU2, and the non-peptide antibacterial agent ceragenin CSA-13.
  2. 02LabIn vitro (cells)Activity measurement

    In vitro, LL‑37 did not keep antibacterial activity against H. pylori after incubation in simulated gastric juice, whereas CSA-13 did.

    In plain wordsIn lab tests, LL‑37 lost its germ-killing activity in simulated stomach juice, but the compound CSA-13 did not.

    Peptide
    LL-37
    Outcome
    DecreaseAntibacterial activity after simulated gastric juice
    Study

    Helicobacter pylorin: not reported in source

    simulated gastric juice (low pH, pepsin)
    Comparator
    Ceragenin CSA-13
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After incubation in simulated gastric juice (low pH with presence of pepsin) CSA-13, but not LL-37 or WLBU2, retained antibacterial activity.
    1 context sentence
    Summary · context
    This study was designed to assess in vitro the anti-H. pylori potential of cathelicidin LL-37 peptide, which is naturally present in gastric juice, its optimized synthetic analog WLBU2, and the non-peptide antibacterial agent ceragenin CSA-13.
  3. 03LabIn vitro (cells)Activity measurement

    In vitro, LL‑37 activity was more strongly inhibited by isolated host gastric mucins than CSA-13 activity.

    In plain wordsIn lab tests, stomach mucus blocked LL‑37 more than it blocked the compound CSA-13.

    Peptide
    LL-37
    Outcome
    DecreaseInhibition by gastric mucins
    Study

    Helicobacter pylorin: not reported in source

    isolated host gastric mucins
    Comparator
    Ceragenin CSA-13
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to LL-37 and WLBU2 peptides, CSA-13 activity was also more resistant to inhibition by isolated host gastric mucins.
    1 context sentence
    Summary · context
    This study was designed to assess in vitro the anti-H. pylori potential of cathelicidin LL-37 peptide, which is naturally present in gastric juice, its optimized synthetic analog WLBU2, and the non-peptide antibacterial agent ceragenin CSA-13.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 04HumanEndogenous levelObservational studyOther

    In gastric mucosa from H. pylori infected subjects, the body's own hCAP-18/LL‑37 expression was increased.

    In plain wordsPeople infected with H. pylori had more of the body's own LL‑37 in the stomach lining.

    Peptide
    LL-37
    Outcome
    IncreasehCAP-18/LL-37 expression in gastric mucosa
    Study

    n: not reported in source

    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    In agreement with previous studies, increased expression of hCAP-18/LL-37 was observed in gastric mucosa obtained from H. pylori infected subjects.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:58 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.